Effect of second-generation sulfonylureas on survival in patients with diabetes mellitus after myocardial infarction

Adelaide M Arruda-Olson, Richard K. Patch, Cynthia L. Leibson, Adrian Vella, Robert L. Frye, Susan A. Weston, Jill M. Killian, Veronique Lee Roger

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

OBJECTIVE: To examine possible adverse effects of sulfonylureas on survival among patients with diabetes mellitus (DM) who experience a myocardial infarction (MI). PATIENTS AND METHODS: Residents of Olmsted County, Minnesota, with an MI that met standardized criteria from January 1, 1985, through December 31, 2002, were followed up for mortality. RESULTS: Among 2189 patients with MI (mean ± SD age, 68±14 years; 1237 men [57%]), 409 (19%) had DM. The 23 patients treated with first-generation sulfonylureas, biguanides, or thiazolidinediones were excluded from analyses. Among the remaining 386 patients with DM, 120 (31%) were taking second-generation sulfonylureas, 180 (47%) were taking insulin, and 86 (22%) were receiving nonpharmacological treatment. Patients with DM treated with second-generation sulfonylureas were more likely to be men and have higher creatinine clearance than those treated with insulin. After adjusting for age, sex, Killip class, duration of DM, creatinine clearance, and reperfusion therapy or revascularization, patients treated with second-generation sulfonylureas had a lower risk of death than did diabetic patients receiving insulin (hazard ratio, 0.41; 95% confidence interval, 0.21-0.80; P=.009). CONCLUSION: These population-based data do not support the concern about an adverse effect of second-generation sulfonylureas on survival after MI and underscore the importance of population-based studies of surveillance of drug safety.

Original languageEnglish (US)
Pages (from-to)28-33
Number of pages6
JournalMayo Clinic Proceedings
Volume84
Issue number1
DOIs
StatePublished - 2009

Fingerprint

Cohort Effect
Diabetes Mellitus
Myocardial Infarction
Survival
Insulin
Creatinine
Biguanides
Thiazolidinediones
Population
Reperfusion
Confidence Intervals
Safety
Mortality
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Effect of second-generation sulfonylureas on survival in patients with diabetes mellitus after myocardial infarction. / Arruda-Olson, Adelaide M; Patch, Richard K.; Leibson, Cynthia L.; Vella, Adrian; Frye, Robert L.; Weston, Susan A.; Killian, Jill M.; Roger, Veronique Lee.

In: Mayo Clinic Proceedings, Vol. 84, No. 1, 2009, p. 28-33.

Research output: Contribution to journalArticle

Arruda-Olson, Adelaide M ; Patch, Richard K. ; Leibson, Cynthia L. ; Vella, Adrian ; Frye, Robert L. ; Weston, Susan A. ; Killian, Jill M. ; Roger, Veronique Lee. / Effect of second-generation sulfonylureas on survival in patients with diabetes mellitus after myocardial infarction. In: Mayo Clinic Proceedings. 2009 ; Vol. 84, No. 1. pp. 28-33.
@article{f49afd9da1134078bd5eaa1b4e06b061,
title = "Effect of second-generation sulfonylureas on survival in patients with diabetes mellitus after myocardial infarction",
abstract = "OBJECTIVE: To examine possible adverse effects of sulfonylureas on survival among patients with diabetes mellitus (DM) who experience a myocardial infarction (MI). PATIENTS AND METHODS: Residents of Olmsted County, Minnesota, with an MI that met standardized criteria from January 1, 1985, through December 31, 2002, were followed up for mortality. RESULTS: Among 2189 patients with MI (mean ± SD age, 68±14 years; 1237 men [57{\%}]), 409 (19{\%}) had DM. The 23 patients treated with first-generation sulfonylureas, biguanides, or thiazolidinediones were excluded from analyses. Among the remaining 386 patients with DM, 120 (31{\%}) were taking second-generation sulfonylureas, 180 (47{\%}) were taking insulin, and 86 (22{\%}) were receiving nonpharmacological treatment. Patients with DM treated with second-generation sulfonylureas were more likely to be men and have higher creatinine clearance than those treated with insulin. After adjusting for age, sex, Killip class, duration of DM, creatinine clearance, and reperfusion therapy or revascularization, patients treated with second-generation sulfonylureas had a lower risk of death than did diabetic patients receiving insulin (hazard ratio, 0.41; 95{\%} confidence interval, 0.21-0.80; P=.009). CONCLUSION: These population-based data do not support the concern about an adverse effect of second-generation sulfonylureas on survival after MI and underscore the importance of population-based studies of surveillance of drug safety.",
author = "Arruda-Olson, {Adelaide M} and Patch, {Richard K.} and Leibson, {Cynthia L.} and Adrian Vella and Frye, {Robert L.} and Weston, {Susan A.} and Killian, {Jill M.} and Roger, {Veronique Lee}",
year = "2009",
doi = "10.4065/84.1.28",
language = "English (US)",
volume = "84",
pages = "28--33",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "1",

}

TY - JOUR

T1 - Effect of second-generation sulfonylureas on survival in patients with diabetes mellitus after myocardial infarction

AU - Arruda-Olson, Adelaide M

AU - Patch, Richard K.

AU - Leibson, Cynthia L.

AU - Vella, Adrian

AU - Frye, Robert L.

AU - Weston, Susan A.

AU - Killian, Jill M.

AU - Roger, Veronique Lee

PY - 2009

Y1 - 2009

N2 - OBJECTIVE: To examine possible adverse effects of sulfonylureas on survival among patients with diabetes mellitus (DM) who experience a myocardial infarction (MI). PATIENTS AND METHODS: Residents of Olmsted County, Minnesota, with an MI that met standardized criteria from January 1, 1985, through December 31, 2002, were followed up for mortality. RESULTS: Among 2189 patients with MI (mean ± SD age, 68±14 years; 1237 men [57%]), 409 (19%) had DM. The 23 patients treated with first-generation sulfonylureas, biguanides, or thiazolidinediones were excluded from analyses. Among the remaining 386 patients with DM, 120 (31%) were taking second-generation sulfonylureas, 180 (47%) were taking insulin, and 86 (22%) were receiving nonpharmacological treatment. Patients with DM treated with second-generation sulfonylureas were more likely to be men and have higher creatinine clearance than those treated with insulin. After adjusting for age, sex, Killip class, duration of DM, creatinine clearance, and reperfusion therapy or revascularization, patients treated with second-generation sulfonylureas had a lower risk of death than did diabetic patients receiving insulin (hazard ratio, 0.41; 95% confidence interval, 0.21-0.80; P=.009). CONCLUSION: These population-based data do not support the concern about an adverse effect of second-generation sulfonylureas on survival after MI and underscore the importance of population-based studies of surveillance of drug safety.

AB - OBJECTIVE: To examine possible adverse effects of sulfonylureas on survival among patients with diabetes mellitus (DM) who experience a myocardial infarction (MI). PATIENTS AND METHODS: Residents of Olmsted County, Minnesota, with an MI that met standardized criteria from January 1, 1985, through December 31, 2002, were followed up for mortality. RESULTS: Among 2189 patients with MI (mean ± SD age, 68±14 years; 1237 men [57%]), 409 (19%) had DM. The 23 patients treated with first-generation sulfonylureas, biguanides, or thiazolidinediones were excluded from analyses. Among the remaining 386 patients with DM, 120 (31%) were taking second-generation sulfonylureas, 180 (47%) were taking insulin, and 86 (22%) were receiving nonpharmacological treatment. Patients with DM treated with second-generation sulfonylureas were more likely to be men and have higher creatinine clearance than those treated with insulin. After adjusting for age, sex, Killip class, duration of DM, creatinine clearance, and reperfusion therapy or revascularization, patients treated with second-generation sulfonylureas had a lower risk of death than did diabetic patients receiving insulin (hazard ratio, 0.41; 95% confidence interval, 0.21-0.80; P=.009). CONCLUSION: These population-based data do not support the concern about an adverse effect of second-generation sulfonylureas on survival after MI and underscore the importance of population-based studies of surveillance of drug safety.

UR - http://www.scopus.com/inward/record.url?scp=58749083391&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58749083391&partnerID=8YFLogxK

U2 - 10.4065/84.1.28

DO - 10.4065/84.1.28

M3 - Article

VL - 84

SP - 28

EP - 33

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 1

ER -